Johnson & Johnson reached a $5.5 billion settlement on 28 July 2026, resolving approximately 69,000 US lawsuits consolidated in federal court in New Jersey, with plaintiffs alleging that talc-based baby powder and related products caused ovarian cancer [Brief - 2026-09-27]. The settlement represents a significant closure to a long-running litigation matter that had been a recurring feature of the company's legal disclosures. The consolidation of claims in federal court in New Jersey formed the procedural basis for the resolution, and the financial terms were publicly confirmed at the time of settlement.
For the trailing twelve months ending 28 June 2026, Johnson & Johnson reported revenue of $97.93 billion, reflecting year-over-year growth of 6.60% [SEC 10-Q - JNJ - 2026-06-28]. Net income over the same period was $21.04 billion, producing a net margin of 21.48%. Gross margin stood at 67.91% and operating margin at 27.37%. EPS declined 0.87% year-over-year. The company held $20.42 billion in cash against total debt of $49.04 billion. The price-to-earnings ratio was recorded at 29.74 as of the filing date.
Five institutional managers opened new positions in JNJ during the most recent reporting period: Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), Bridgewater (Ray Dalio), and Soros Fund Management (George Soros) each initiated new holdings [SEC 13F - Citadel - Q3 2026] [SEC 13F - AQR Capital - Q3 2026] [SEC 13F - Millennium - Q3 2026] [SEC 13F - Bridgewater - Q3 2026] [SEC 13F - Soros Fund Mgmt - Q3 2026]. The simultaneous entry of multiple large institutional managers across a single quarter represents a notable concentration of new institutional activity in the stock. No insider transaction data was available for inclusion in this report.
The prevailing macroeconomic environment showed the 10-year US Treasury yield at 5.24% and the 2-year yield at 4.78%, producing a normal yield curve with a spread of 46 basis points [FRED DGS10] [FRED DGS2]. This rate environment forms part of the broader context in which JNJ's debt position of $49.04 billion and cash holdings of $20.42 billion are reported. This report was generated in response to material institutional position changes identified in the most recent 13F filings.